Xellia and Kabi Broaden US Antibiotics Offering
New Offerings Of Vancomycin And Ertapenem
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.
You may also be interested in...
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.